An Introduction to the Psychedelic Renaissance
40% of American adults report struggling with mental health or substance abuse disorders. Psychedelics may provide solutions to the global mental health and wellbeing crisis.
After decades of repression, psychedelic research is thriving.
Decriminalisation and legalisation campaigns are succeeding.
In 2020 the U.S. state of Oregon voted to decriminalise psychedelics and legalise Psilocybin Therapy. Washington, D.C., home of the White House, also decriminalised psychedelics, with many other states and localities poised to follow suit and nascent discussions at the federal level. Canada’s Health Minister has granted exemptions to allow access to psilocybin-assisted psychotherapy, setting precedent for future efforts to expand access.
Significant clinical trial milestones on the horizon.
In a Phase 3 MDMA-assisted therapy for PTSD trial that published in 2021, 88% of participants responded to the treatment. The trial’s sponsor, MAPS, expects to submit a New Drug Application to the FDA this year, with a potential approval in 2024.. Multiple trials of psilocybin for depression are in Phase 2, with one Phase 3 program underway, and are indicating preliminary safety and efficacy.
Psychedelics have the potential to address depression anxiety addiction PTSD chronic pain
Welcome to the Psychedelic Renaissance.
Our most popular psychedelic sector resources.
The Psychedelic Renaissance in Context
Today’s psychedelic renaissance benefits from a rich legacy of psychedelic research and usage dating back to pre-historic times.
The extensive psychedelic research and experimentation of the 1950s and ’60s represents a significant endowment, with today’s researchers taking up the torch.
Albert Hofmann intentionally ingests LSD, experiencing the effects while cycling home. “Bicycle Day” is coined.
mid 1960s – 1971
Psychedelics criminalised, with Nixon declaring a War on Drugs in 1971 and a UN Convention following suit.
Psychedelic iconography, such as mushrooms, appear in etched murals dating 10,000 BCE.
1950s and ’60s
Fertile decades for psychedelics research and experimentation, particularly in the U.S.
Psychedelic renaissance emerges, with a return to human studies of psychedelics and decriminalisation campaigns.
Our Latest Analysis
Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)
Our dispatch from ECNP’s 2023 New Frontiers meeting, which this year focused on Psychedelics. We recap the main themes under discussion…
Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at SXSW; Could MDMA Be Among First Beneficiaries of Faster UK Drug Approvals?
This week: UK set to make drug approvals ‘faster and nimbler’, which could help MDMA-assisted therapy; ketamine clinics close, which could damage future PAT infrastructure; psychedelics at SXSW; and lots more…
Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?
This week: we look at changes to COMPASS’ Phase 3 program; the Stamets Stack’s patent; and, we evaluate Zuranolone as a potential comp for psychedelic therapies. Plus lots more…
Receive Our Updates
Join our Newsletter
Psychedelic insights, commentary and analysis delivered to your inbox, including our weekly Bulletin.
Follow Us on Twitter
Join us on Twitter where we share the latest news and analysis, covering the entire psychedelic space.